Medical, News, Uncategorized

Immunomodulatory and Antidiabetic Effects of a New Herbal Preparation (HemoHIM)

Angelica gigas Nakai, Cnidium officinale Makino, and Paeonia japonica Miyabe) was developed to protect immune, hematopoietic, and self-renewal tissues against radiation.

This study determined whether or not HemoHIM could alter hyperglycemia and the immune response in diabetic mice.

Both nondiabetic and diabetic mice were orally administered HemoHIM (100 mg/kg) once a day for 4 weeks. Diabetes was induced by single injection of streptozotocin (STZ, 200 mg/kg, i.p.).

In diabetic mice, HemoHIM effectively improved hyperglycemia and glucose tolerance compared to the diabetic control group as well as elevated plasma insulin levels with preservation of insulin staining in pancreatic β-cells.

HemoHIM treatment restored thymus weight, white blood cells, lymphocyte numbers, and splenic lymphocyte populations (CD4(+) T and CD8(+) T), which were reduced in diabetic mice, as well as IFN-γ production in response to Con A stimulation.

These results indicate that HemoHIM may have potential as a glucose-lowering and immunomodulatory agent by enhancing the immune function of pancreatic β-cells in STZ-induced diabetic mice.

Resources:

https://www.ncbi.nlm.nih.gov/m/pubmed/25045390/?i=3&from=hemohim

—————————————————————–

Here is Hemohim Developed and Produced and Now Market by Atomy

Sign Up Free to Purchase Atomy at Wholesale Price

atomy-hemohim-plus-420x286

Advertisements
Health Care, Medical, News, Products, Uncategorized

HemoHIM, a herbal preparation, alleviates airway inflammation

HemoHIM, a herbal preparation, alleviates airway inflammation caused by cigarette smoke and lipopolysaccharide.

HemoHIM, herbal preparation has designed for immune system recovery.

We investigated the anti-inflammatory effect of HemoHIM on cigarette smoke (CS) and lipopolysaccharide (LPS) induced chronic obstructive pulmonary disease (COPD) mouse model.

To induce COPD, C57BL/6 mice were exposed to CS for 1 h per day (eight cigarettes per day) for 4 weeks and intranasally received LPS on day 26. HemoHIM was administrated to mice at a dose of 50 or 100 mg/kg 1h before CS exposure.

HemoHIM reduced the inflammatory cell count and levels of tumor necrosis factor receptor (TNF)-α, interleukin (IL)-6 and IL-1β in the broncho-alveolar lavage fluid (BALF) induced by CS+LPS exposure. HemoHIM decreased the inflammatory cell infiltration in the airway and inhibited the expression of iNOS and MMP-9 and phosphorylation of Erk in lung tissue exposed to CS+LPS.

In summary, our results indicate that HemoHIM inhibited a reduction in the lung inflammatory response on CS and LPS induced lung inflammation via the Erk pathway. Therefore, we suggest that HemoHIM has the potential to treat pulmonary inflammatory disease such as COPD.

Resources:

Shin NR, et al. Lab Anim Res. 2017.
Authors

Author information

1
College of Veterinary Medicine (BK21 Plus Project Team), Chonnam National University, Gwangju, Korea.
2
Natural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Korea.

Citation

Lab Anim Res. 2017 Mar;33(1):40-47. doi: 10.5625/lar.2017.33.1.40. Epub 2017 Mar 27.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385281/

————————————————————

Here is Hemohim Developed and Produced and Now Market by Atomy

Sign Up Free to Purchase Atomy at Wholesale Price

atomy-hemohim-plus-420x286